Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Status: RECRUITING

Eligibility Criteria

Age: Not specified

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

* Received a regimen containing one or more immuno-oncology therapeutics * Must have experienced one or more of the following: * One or more serious (Grade 3-4) AEs that are likely immune-related * One or more Grade 2 dermatologic or rheumatologic AEs that are likely immune-related * Diagnosis of a rare infection, e.g., fungal or mycobacterial, after starting IO treatment ** Note: Diagnosis of SARS-CoV-2 (COVID-19) is excluded * Hyperprogression. Image submission for patients experiencing hyperprogression is required. For assistance in determining hyperprogression for purposes of eligibility, institutions may contact the study chair and submit images for central review * Has not previously been registered to this study

Conditions & Interventions

Interventions:
PROCEDURE: Biospecimen Collection, OTHER: Medical Chart Review
Conditions:
Malignancy

More Information

Contact(s): David Kozono, MD, PhD - dkozono@bwh.harvard.edu
Principal Investigator:
Phase:
IRB
Number:
System ID: NCT04242095